-
1
-
-
0036142522
-
Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors
-
Kimyai-Asadi A, Jih MH: Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 2002; 138: 129-131.
-
(2002)
Arch Dermatol
, vol.138
, pp. 129-131
-
-
Kimyai-Asadi, A.1
Jih, M.H.2
-
2
-
-
84864872002
-
Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitorrelated papulopustular eruption: An effective and convenient alternative to tetracyclines
-
Nikolaou V, Strimpakos AS, Stratigos A, Katsambas A, Antoniou C, Syrigos KN: Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitorrelated papulopustular eruption: an effective and convenient alternative to tetracyclines. Dermatology 2012; 224: 315-319.
-
(2012)
Dermatology
, vol.224
, pp. 315-319
-
-
Nikolaou, V.1
Strimpakos, A.S.2
Stratigos, A.3
Katsambas, A.4
Antoniou, C.5
Syrigos, K.N.6
-
3
-
-
33847012963
-
Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy
-
DeWitt CA, Siroy AE, Stone SP: Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007; 56: 500-505.
-
(2007)
J Am Acad Dermatol
, vol.56
, pp. 500-505
-
-
Dewitt, C.A.1
Siroy, A.E.2
Stone, S.P.3
-
4
-
-
35548969264
-
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management
-
Lynch TJ Jr, Kim ES, Eaby B, Garey J, West DP, Lacouture ME: Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12: 610-621.
-
(2007)
Oncologist
, vol.12
, pp. 610-621
-
-
Lynch Jr., T.J.1
Kim, E.S.2
Eaby, B.3
Garey, J.4
West, D.P.5
Lacouture, M.E.6
-
5
-
-
77951879709
-
Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: A case series and a literature review of therapeutic approaches
-
Nikolaou V, Stratigos A, Antoniou C, et al: Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches. Dermatology 2010; 220: 243-248.
-
(2010)
Dermatology
, vol.220
, pp. 243-248
-
-
Nikolaou, V.1
Stratigos, A.2
Antoniou, C.3
-
6
-
-
0033757709
-
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
-
suppl 1)
-
Raymond E, Faivre S, Armand JP: Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60(suppl 1):15-23.
-
(2000)
Drugs
, vol.60
, pp. 15-23
-
-
Raymond, E.1
Faivre, S.2
Armand, J.P.3
-
7
-
-
0028955388
-
Epidermal growth factor-related peptides and their receptors in human malignancies
-
Salomon DS, Brandt R, Ciardiello F, Normanno N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
-
(1995)
Crit Rev Oncol Hematol
, vol.19
, pp. 183-232
-
-
Salomon, D.S.1
Brandt, R.2
Ciardiello, F.3
Normanno, N.4
-
8
-
-
0033063774
-
The epidermal growth factor receptor and its inhibition in cancer therapy
-
Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-250.
-
(1999)
Pharmacol Ther
, vol.82
, pp. 241-250
-
-
Woodburn, J.R.1
-
9
-
-
3242720345
-
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
-
Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-345.
-
(2004)
N Engl J Med
, vol.351
, pp. 337-345
-
-
Cunningham, D.1
Humblet, Y.2
Siena, S.3
-
10
-
-
2142641698
-
Phase ii trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
-
Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ: Phase ii trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1201-1208
-
-
Saltz, L.B.1
Meropol, N.J.2
Loehrer Sr., P.J.3
Needle, M.N.4
Kopit, J.5
Mayer, R.J.6
-
11
-
-
38549088386
-
Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae
-
Wagner LI, Lacouture ME: Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 2007; 21(11 suppl 5): 34-36.
-
(2007)
Oncology (Williston Park)
, vol.21
, Issue.11 SUPPL. 5
, pp. 34-36
-
-
Wagner, L.I.1
Lacouture, M.E.2
-
12
-
-
34249933404
-
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase iii trial of the national cancer institute of Canada clinical trials group
-
Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase iii trial of the national cancer institute of Canada clinical trials group. J Clin Oncol 2007; 25: 1960-1966.
-
(2007)
J Clin Oncol
, vol.25
, pp. 1960-1966
-
-
Moore, M.J.1
Goldstein, D.2
Hamm, J.3
-
13
-
-
22044445517
-
Erlotinib in previously treated nonsmall-cell lung cancer
-
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005; 353: 123-132.
-
(2005)
N Engl J Med
, vol.353
, pp. 123-132
-
-
Shepherd, F.A.1
Rodrigues Pereira, J.2
Ciuleanu, T.3
-
14
-
-
1542713370
-
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2
-
Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22: 785-794.
-
(2004)
J Clin Oncol
, vol.22
, pp. 785-794
-
-
Herbst, R.S.1
Giaccone, G.2
Schiller, J.H.3
-
15
-
-
76649083897
-
Lenalidomide-induced acute acneiform folliculitis of the head and neck: Not only the anti-EGF receptor agents
-
Michot C, Guillot B, Dereure O: Lenalidomide-induced acute acneiform folliculitis of the head and neck: not only the anti-EGF receptor agents. Dermatology 2010; 220: 49-50.
-
(2010)
Dermatology
, vol.220
, pp. 49-50
-
-
Michot, C.1
Guillot, B.2
Dereure, O.3
-
16
-
-
27844440990
-
Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia
-
Gambillara E, Laffitte E, Widmer N, et al: Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology 2005; 211: 363-365.
-
(2005)
Dermatology
, vol.211
, pp. 363-365
-
-
Gambillara, E.1
Laffitte, E.2
Widmer, N.3
-
17
-
-
27844586914
-
Sirolimus-induced acneiform eruption
-
Kunzle N, Venetz JP, Pascual M, Panizzon RG, Laffitte E: Sirolimus-induced acneiform eruption. Dermatology 2005; 211: 366-369.
-
(2005)
Dermatology
, vol.211
, pp. 366-369
-
-
Kunzle, N.1
Venetz, J.P.2
Pascual, M.3
Panizzon, R.G.4
Laffitte, E.5
-
18
-
-
0036139727
-
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition
-
Albanell J, Rojo F, Averbuch S, et al: Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110-124.
-
(2002)
J Clin Oncol
, vol.20
, pp. 110-124
-
-
Albanell, J.1
Rojo, F.2
Averbuch, S.3
-
19
-
-
0035724536
-
Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225
-
Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC: Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169-1176.
-
(2001)
Br J Dermatol
, vol.144
, pp. 1169-1176
-
-
Busam, K.J.1
Capodieci, P.2
Motzer, R.3
Kiehn, T.4
Phelan, D.5
Halpern, A.C.6
-
20
-
-
12444259660
-
Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients
-
Malik SN, Siu LL, Rowinsky EK, et al: Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003; 9: 2478-2486.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 2478-2486
-
-
Malik, S.N.1
Siu, L.L.2
Rowinsky, E.K.3
-
21
-
-
0028179669
-
P27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest
-
Polyak K, Kato JY, Solomon MJ, et al: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
-
(1994)
Genes Dev
, vol.8
, pp. 9-22
-
-
Polyak, K.1
Kato, J.Y.2
Solomon, M.J.3
-
22
-
-
63249120652
-
Malassezia folliculitis presented as acneiform eruption after cetuximab administration
-
Cholongitas E, Pipili C, Ioannidou D: Malassezia folliculitis presented as acneiform eruption after cetuximab administration. J Drugs Dermatol 2009; 8: 274-275.
-
(2009)
J Drugs Dermatol
, vol.8
, pp. 274-275
-
-
Cholongitas, E.1
Pipili, C.2
Ioannidou, D.3
-
23
-
-
79955692259
-
Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors
-
Gerber PA, Kukova G, Buhren BA, Homey B: Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology 2011; 222: 144-147.
-
(2011)
Dermatology
, vol.222
, pp. 144-147
-
-
Gerber, P.A.1
Kukova, G.2
Buhren, B.A.3
Homey, B.4
-
24
-
-
41449095523
-
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: Results of an experts panel meeting
-
Gridelli C, Maione P, Amoroso D, et al: Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an experts panel meeting. Crit Rev Oncol Hematol 2008; 66: 155-162.
-
(2008)
Crit Rev Oncol Hematol
, vol.66
, pp. 155-162
-
-
Gridelli, C.1
Maione, P.2
Amoroso, D.3
-
25
-
-
37349121157
-
Erlotinib-induced florid acneiform rash complicated by extensive impetiginization
-
Kardaun SH, van Duinen KF: Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. Clin Exp Dermatol 2008; 33: 46-49.
-
(2008)
Clin Exp Dermatol
, vol.33
, pp. 46-49
-
-
Kardaun, S.H.1
Van Duinen, K.F.2
|